![Theresa Visarius](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Theresa Visarius
Corporate Officer/Principal bei Immunophotonics, Inc.
Aktive Positionen von Theresa Visarius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Corporate Officer/Principal | - | - |
Karriereverlauf von Theresa Visarius
Ehemalige bekannte Positionen von Theresa Visarius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Medyria AG
![]() Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
General Counsel | - | - |
Ausbildung von Theresa Visarius
University of Bern | Doctorate Degree |
Statistik
International
Schweiz | 3 |
Vereinigte Staaten | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
General Counsel | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Medyria AG
![]() Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Health Technology |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Börse
- Insiders
- Theresa Visarius
- Erfahrung